{
    "clinical_study": {
        "@rank": "55175", 
        "acronym": "LEGEND", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "24-week treatment period: starting dose will be of 2/1000 mg  or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M\u00ae ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M\u00ae , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values \u2264 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia."
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      -To demonstrate the efficacy of a fixed combination of glimepiride + metformin in terms of\n      HbA1c reduction, during 24-week treatment period in patients with inadequately controlled\n      type 2 diabetes mellitus.\n\n      Secondary Objective:\n\n      To assess the effects of the fixed combination of glimepiride and metformin at week 24 on:\n\n        -  Percentage of patients reaching HbA1c <7%\n\n        -  Percentage of patients reaching HbA1c <6.5%.\n\n        -  Fasting Plasma Glucose (FPG)\n\n        -  Safety and tolerability"
        }, 
        "brief_title": "Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study duration for each patient is approximately 27 weeks with 3 periods: 2-week\n      screening period followed by 24-week treatment period and 3 days follow-up period with a\n      last call phone visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with type 2 diabetes mellitus inadequately controlled despite a treatment\n             with sulfonylurea (SU) alone or metformin alone or a free combination of SU and\n             metformin prior to the study entry.\n\n          -  Signed informed consent,  obtained prior any study procedure\n\n        Exclusion criteria:\n\n          -  Age < legal age of adulthood\n\n          -  HbA1c < 7% or \u2265 11%\n\n          -  BMI > 35 kg/m2\n\n          -  Treatment with a stable dose of maximally tolerated SU alone or metformin alone or\n             the free combination of SU and metformin for less than 12 weeks prior to the\n             screening visit.\n\n          -  Patients who received any anti-diabetic drug other than SU or metformin within 12\n             weeks prior to the screening visit.\n\n          -  Diabetes other than type 2 diabetes  (e.g. type 1 diabetes, diabetes secondary to\n             pancreatic disorders, drug or chemical agent intake\u2026)\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "167", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699932", 
            "org_study_id": "GLMET_R_05823", 
            "secondary_id": "U1111-1120-0058"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "description": "Pharmaceutical form:tablet\nRoute of administration: oral", 
            "intervention_name": "Glimepiride+metformin (Amaryl M\u00ae) - HOE4900", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon"
                    }, 
                    "name": "Investigational Site Number 422-002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hazmieh", 
                        "country": "Lebanon"
                    }, 
                    "name": "Investigational Site Number 422-001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samara", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Investigational Site Number 643001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Investigational Site Number 643002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Investigational Site Number 643-03"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chernivtsi", 
                        "country": "Ukraine", 
                        "zip": "58022"
                    }, 
                    "name": "Investigational Site Number 804003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine", 
                        "zip": "83099"
                    }, 
                    "name": "Investigational Site Number 804001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine", 
                        "zip": "83059"
                    }, 
                    "name": "Investigational Site Number 804004"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine", 
                        "zip": "83003"
                    }, 
                    "name": "Investigational Site Number 804008"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odessa", 
                        "country": "Ukraine"
                    }, 
                    "name": "Investigational Site Number 804010"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poltava", 
                        "country": "Ukraine", 
                        "zip": "36011"
                    }, 
                    "name": "Investigational Site Number 804006"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnytsya", 
                        "country": "Ukraine", 
                        "zip": "21029"
                    }, 
                    "name": "Investigational Site Number 804002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnytsya", 
                        "country": "Ukraine", 
                        "zip": "21010"
                    }, 
                    "name": "Investigational Site Number 804007"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Lebanon", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multinational, Open Label, Non Comparative, 24-week Study to Evaluate the Blood Glucose Lowering Efficacy and Safety of a Fixed Dose Combination of Glimepiride and Metformin in Patients With Inadequately Controlled Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Lebanon: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c", 
            "safety_issue": "No", 
            "time_frame": "from baseline to week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699932"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with HbA1c < 7%", 
                "safety_issue": "No", 
                "time_frame": "at week 24"
            }, 
            {
                "measure": "Percentage of patients with HbA1c < 6.5%", 
                "safety_issue": "No", 
                "time_frame": "at week 24"
            }, 
            {
                "measure": "Change in Fasting Plasma Glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to week 24"
            }, 
            {
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "over the 24-week treatment period"
            }, 
            {
                "measure": "Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "over the 24-week treatment period"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}